| SC 13G | 2024-02-14 | Nantahala Capital Management, LLC | ZEVRA THERAPEUTICS, INC. | 2,453,405 | 6.2% | EDGAR |
| SC 13G | 2024-01-29 | BlackRock Inc. | ZEVRA THERAPEUTICS, INC. | 2,410,289 | 5.8% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | KEMPHARM, INC | 852,849 | 2.5% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | KEMPHARM, INC | 2,235,542 | 6.3% | EDGAR |
| SC 13G/A | 2022-01-12 | Braun Samuel J | KEMPHARM, INC | 3,021,660 | 8.6% | EDGAR |
| SC 13G/A | 2022-01-11 | Empery Asset Management, LP | KEMPHARM, INC | 801,670 | 2.2% | EDGAR |
| SC 13D | 2021-12-01 | Braun Samuel J | KEMPHARM, INC | 3,377,560 | 9.6% | EDGAR |
| SC 13G/A | 2021-05-17 | Braun Samuel J | KEMPHARM, INC | 3,155,000 | 11.1% | EDGAR |
| SC 13G | 2021-04-19 | Braun Samuel J | KEMPHARM, INC | 2,056,500 | 7.2% | EDGAR |
| SC 13G/A | 2021-03-09 | Mangless Daniel John | KEMPHARM, INC | 10 | 3.7% | EDGAR |
| SC 13G/A | 2021-02-16 | Delaware Street Capital Master Fund, L.P. | KEMPHARM, INC | 159,364 | 3.4% | EDGAR |
| SC 13G/A | 2021-02-12 | Mickle Travis C | KEMPHARM, INC | 227,545 | 4.9% | EDGAR |
| SC 13G/A | 2021-02-12 | Auctus Fund, LLC | KEMPHARM, INC | 450,000 | 2.4% | EDGAR |
| SC 13G | 2021-02-05 | Auctus Fund, LLC | KEMPHARM, INC | 1,000,000 | 8.6% | EDGAR |
| SC 13G | 2021-01-14 | Empery Asset Management, LP | KEMPHARM, INC | 1,125,000 | 10.0% | EDGAR |
| SC 13G/A | 2020-02-14 | Mickle Travis C | KEMPHARM, INC | 3,252,280 | 8.9% | EDGAR |
| SC 13G/A | 2020-02-14 | Alyeska Investment Group, L.P. | KEMPHARM, INC | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-11 | Mangless Daniel John | KEMPHARM, INC | 10 | 6.0% | EDGAR |
| SC 13G | 2019-06-11 | Mangless Daniel John | KEMPHARM, INC | 10 | 5.3% | EDGAR |
| SC 13G/A | 2019-02-14 | Alyeska Investment Group, L.P. | KEMPHARM, INC | 1,825,000 | 6.9% | EDGAR |